Condensed Statements of Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Total		Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021			36,083,301
Beginning balance at Dec. 31, 2021	$ 199,059		$ 3	$ 414,348	$ (201)	$ (215,091)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)			15,606
Vesting of restricted stock awards	1			1
Option exercises (in shares)			63,552
Option exercises	51			51
Stock-based compensation expense	3,531			3,531
Net unrealized loss on short-term investments	(749)				(749)
Net loss	(28,100)					(28,100)
Ending balance (in shares) at Mar. 31, 2022			36,162,459
Ending balance at Mar. 31, 2022	173,793		$ 3	417,931	(950)	(243,191)
Beginning balance (in shares) at Dec. 31, 2021			36,083,301
Beginning balance at Dec. 31, 2021	199,059		$ 3	414,348	(201)	(215,091)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized loss on short-term investments	(1,058)
Net loss	(57,646)
Ending balance (in shares) at Jun. 30, 2022			36,182,297
Ending balance at Jun. 30, 2022	147,788		$ 3	421,781	(1,259)	(272,737)
Beginning balance (in shares) at Mar. 31, 2022			36,162,459
Beginning balance at Mar. 31, 2022	173,793		$ 3	417,931	(950)	(243,191)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of restricted stock awards (in shares)			6,235
Vesting of restricted stock awards	1			1
Option exercises (in shares)			13,603
Option exercises	446			446
Stock-based compensation expense	3,403			3,403
Net unrealized loss on short-term investments	(309)				(309)
Net loss	(29,546)					(29,546)
Ending balance (in shares) at Jun. 30, 2022			36,182,297
Ending balance at Jun. 30, 2022	$ 147,788		$ 3	421,781	(1,259)	(272,737)
Beginning balance (in shares) at Dec. 31, 2022	48,941,254		48,941,254
Beginning balance at Dec. 31, 2022	$ 313,342	[1]	$ 5	653,707	(1,958)	(338,412)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued in a public offering, net of offering expenses (in shares)			9,583,334
Common stock issued in a public offering, net of offering expenses	269,915		$ 1	269,914
Option exercises (in shares)			454,314
Option exercises	3,661			3,661
Stock-based compensation expense	11,923			11,923
Net unrealized loss on short-term investments	627				627
Net loss	(37,548)					(37,548)
Ending balance (in shares) at Mar. 31, 2023			58,978,902
Ending balance at Mar. 31, 2023	$ 561,920		$ 6	939,205	(1,331)	(375,960)
Beginning balance (in shares) at Dec. 31, 2022	48,941,254		48,941,254
Beginning balance at Dec. 31, 2022	$ 313,342	[1]	$ 5	653,707	(1,958)	(338,412)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net unrealized loss on short-term investments	(283)
Net loss	$ (78,740)
Ending balance (in shares) at Jun. 30, 2023	59,222,685		59,222,685
Ending balance at Jun. 30, 2023	$ 533,065		$ 6	952,452	(2,241)	(417,152)
Beginning balance (in shares) at Mar. 31, 2023			58,978,902
Beginning balance at Mar. 31, 2023	561,920		$ 6	939,205	(1,331)	(375,960)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Public offering expenses	(133)			(133)
Option exercises (in shares)			243,783
Option exercises	334			334
Stock-based compensation expense	13,046			13,046
Net unrealized loss on short-term investments	(910)				(910)
Net loss	$ (41,192)					(41,192)
Ending balance (in shares) at Jun. 30, 2023	59,222,685		59,222,685
Ending balance at Jun. 30, 2023	$ 533,065		$ 6	$ 952,452	$ (2,241)	$ (417,152)

[1] The condensed balance sheet as of December 31, 2022 has been derived from the audited financial statements as of that date.